일반총설 : 나노입자를 이용한 표적전달 및 암치료 = Targeted Delivery of Nanoparticles for Cancer Treatment

참고문헌 (Reference)

1 김유한, "폴리비닐알코올의 약물전달체 응용" 한국조직공학과 재생의학회 3 (3): 96-100, 2006

2 MB Yatvin, "pH-sensitive liposomes: possible clinical implications" 210 : 1253-, 1980

3 F Yuan, "Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size" 55 : 3752-, 1995

4 BJ Hicke, "Tumor targeting by an aptamer" 47 : 668-, 2006

5 LT Chen, "The role of the sinus wall in the passage of erythrocytes through the spleen" 41 : 529-, 1973

6 H Maeda, "The enhanced permeability and retention(EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting" 41 : 189-, 2001

7 R Duncan, "The dawning era of polymer therapeutics" 2 : 347-, 2003

8 JS Ross, "Targeted therapies for cancer 2004" 122 : 598-609, 2004

9 OC Farokhzad, "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo" 6315-, 2006

10 ZM Qian, "Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway" 54 : 561-, 2002

11 DA Eavarone, "Targeted drug delivery to C6 glioma by transferrin-coupled liposomes" 51 : 10-, 2000

12 W Wu, "Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes" 44 : 6358-, 2005

13 R Bhatt, "Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin" 46 : 190-, 2003

14 E Wisse, "Structure and function of sinusoidal lining cells in the liver" 24 : 100-, 1996

15 SM Moghimi, "Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties" 42 : 463-, 2003

16 F Morgillo, "Resistance to epidermal growth factor receptor-targeted therapy" 8 : 298-, 2005

17 SM Moghimi, "Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups" 18 : 1-, 2001

18 PS Gill, "Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma" 14 : 2353-, 1996

19 AW Tolcher, "Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer" 17 : 478-, 1999

20 C Li, "Poly(L-glutamic acid)--anticancer drug conjugates" 54 : 695-, 2002

21 LT Baxter, "Physiologicallybased pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice" 54 : 1517-, 1994

22 E Rosenthal, "Phase IV study of liposomal daunorubicin DaunoXome) in AIDS-related Kaposi sarcoma" 25 : 57-, 2002

23 WJ Gradishar, "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer" 23 : 7794-, 2005

24 P Sabbatini, "Phase II study of CT-2103 in patients with recurrent epithelial ovarian,fallopian tube, or primary peritoneal carcinoma" 22 : 4523-, 2004

25 PA Vasey, "Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member ofa new class of chemotherapeutic agents-drug-polymer conjugates" 5 : 83-, 1999

26 DW Nyman, "Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies" 23 : 7785-, 2005

27 JM Harris, "Pegylation: a novel process for modifying pharmacokinetics" 40 : 539-, 2001

28 M Markman, "Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary" 7 : 1469-, 2006

29 L Cerchia, "Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase" 3 : e123-, 2005

30 OC Farokhzad, "Nanoparticle- aptamer bioconjugates: a new approach for targeting prostate cancer cells" 64 : 7668-, 2004

31 JF Kukowska-Latallo, "Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer" 65 : 5317-, 2005

32 M Rawat, "Nanocarriers: promising vehicle for bioactive drugs" 29 : 1790-, 2006

33 N Nasongkla, "Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems" 6 : 2427-, 2006

34 MM Gottesman, "Multidrug resistance in cancer: role of ATP-dependent transporters" 2 : 48-, 2002

35 JS Park, "Microemulsions as carriers for drugs and nutraceuticals" 4 (4): 502-, 2007

36 ZM Qian, "Mechanisms of iron uptake by mammalian cells" 1269 : 205-, 1995

37 EI Deryugina, "Matrix metalloproteinases and tumor metastasis" 25 : 9-, 2006

38 MA Saksena, "Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging" 58 : 367-, 2006

39 O Ishida, "Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo" 18 : 1042-, 2001

40 DC Drummond, "Liposome targeting to tumors using vitamin and growth factor receptors" 60 : 285-, 2000

41 RD Hofheinz, "Liposomal encapsulated anti-cancer drugs" 16 : 691-, 2005

42 TM Allen, "Ligand-targeted therapeutics in anticancer therapy" 2 : 750-, 2002

43 C Bies, "Lectin-mediated drug targeting: history and applications" 56 : 425-, 2004

44 K Cho, "Investigation of taxolresistance using folate-targeted ternary therapeutic nanoparticle" 2311-, 2007

45 H Iinuma, "Intracellular targeting therapy of cisplatin-encapsulated transferrinpolyethylene glycol liposome on peritoneal dissemination of gastric cancer" 99 : 130-, 2002

46 YW Cho, "In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles : Mechanisms, key factors, and their implications" 28 : 1236-, 2007

47 K Maruyama, "Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo" 413 : 177-, 1997

48 RO Dillman, "Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies" 9 : 17-, 1994

49 LW Seymour, "Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin" 20 : 1668-, 2002

50 H Pelicano, "Glycolysis inhibition for anticancer treatment" 25 : 4633-, 2006

51 CP Leamon, "Folate-targeted chemotherapy" 56 : 1127-, 2004

52 W Seo, "FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents" 5 : 971-, 2006

53 NF Saba, "Examining expression of folate receptors in squamous cell carcinoma of the head and neck (SCCHN) as a target for nanotherapeutic drugs" LB174-, 2007

54 S Bennis, "Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexyl-cyanoacrylate nanospheres against multidrug-resistant tumour cells in culture" 30 : 89-, 1994

55 SK Sahoo, "Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention" 2 : 373-, 2005

56 T Minko, "Drug targeting to the colon with lectins and neoglycoconjugates" 56 : 491-, 2004

57 ES Lee, "Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor" 103 : 405-, 2005

58 G Pastorin, "Double functionalisation of carbon nanotubes for multimodal drug delivery" 1182 : 2006

59 T Nakanishi, "Development of the polymer micelle carrier system for doxorubicin" 74 : 295-, 2001

60 S Svenson, "Dendrimers in biomedical applicationsreflections on the field" 57 : 2106-, 2005

61 N Malik, "Dendrimer-platinate: a novel approach to cancer chemotherapy" 10 : 767-, 1999

62 E Rivera, "Current status of liposomal anthracycline therapy in metastatic breast cancer" 4 : S76-, 2003

63 NW Kam, "Carbon nanotubes as multifunctional biological transporters andnearinfrared agents for selective cancer cell destruction" 102 : 11600-, 2005

64 A Bianco, "CD Partidos, et al., Biomedical applications of functionalised carbon nanotubes" 571 : 2005

65 JS Park, "Biodegradable polymer microspheres for controlled drug release" 4 (4): 347-, 2007

66 R Gref, "Biodegradable long-circulating polymeric nanospheres" 263 : 1600-, 1994

67 EN Brody, "Aptamers as therapeutic and diagnostic agents" 74 : 5-, 2000

68 A Bianco, "Applications of carbon nanotubes in drug delivery" 9 : 674-, 2005

69 KS Schmidt, "Application of locked nucleic acids to improve aptamer in vivo stability and targeting function" 32 : 5757-, 2004

70 EV Batrakova, "Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anticancer activity" 74 : 1545-, 1996

71 P Carmeliet, "Angiogenesis in cancer and other diseases" 407 : 249-, 2000

72 MR Green, "Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment ofadvanced non-small-cell lung cancer" 17 : 1263-, 2006

73 AM Mansour, "A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2" 63 : 4062-, 2003

74 HL Wong, "A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system" 317 : 1372-, 2006

75 J Wu, "A folate receptor-targeted liposomal formulation for paclitaxel" 316 : 148-, 2006

76 ML Adams, "A Lavasanifar, GS Kwon, Amphiphilic block copolymers for drug delivery" 92 : 1343-, 2003